ImmuPharma (LON:IMM)‘s stock had its “corporate” rating reissued by investment analysts at Northland Securities in a note issued to investors on Friday.
Shares of LON:IMM opened at GBX 19.82 ($0.26) on Friday. ImmuPharma has a 1 year low of GBX 44 ($0.57) and a 1 year high of GBX 193.74 ($2.50).
ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Read More: What is the NASDAQ Stock Market?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.